Sergliflozin etabonate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sergliflozin etabonate
Sergliflozin etabonate 2.svg
Systematic (IUPAC) name
2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Clinical data
Legal status
Routes Oral
CAS number 408504-26-7 YesY
ATC code None
PubChem CID 9824918
ChemSpider 21234810 N
Chemical data
Formula C23H28O9 
Mol. mass 448.463 g/mol
 N (what is this?)  (verify)

Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.[citation needed]

Method of action[edit]

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]


Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.